

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Kumar Neil</u> (Last) (First) (Middle) C/O EIDOS THERAPEUTICS, INC. 101 MONTGOMERY STREET, SUITE 2550 (Street) SAN FRANCISCO CA 94104 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Eidos Therapeutics, Inc. [EIDX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) Chief Executive Officer
	3. Date of Earliest Transaction (Month/Day/Year) 06/22/2018	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/22/2018		C		18,826,417	A	\$0.00	18,826,417	I	See footnote ⁽²⁾
Common Stock	06/22/2018		F		211,762	D	\$17	18,614,655	I	See footnote ⁽²⁾
Common Stock	06/22/2018		P		1,000,000	A	\$17	19,614,655	I	See footnote ⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Warrants	\$10.8348	06/22/2018		X			332,262	(1)	(1)	Series B Preferred Stock	332,262	\$0.00	0	I	See footnote ⁽²⁾
Series B Convertible Preferred Stock	(3)	06/22/2018		X		332,262		(3)	(3)	Common Stock	397,385	\$0.00	2,909,029	I	See footnote ⁽²⁾
Series B Convertible Preferred Stock	(3)	06/22/2018		C		2,909,029		(3)	(3)	Common Stock	3,479,198	\$0.00	0	I	See footnote ⁽²⁾
Series Seed Preferred Stock	(3)	06/22/2018		C		12,832,123		(3)	(3)	Common Stock	15,347,219	\$0.00	0	I	See footnote ⁽²⁾

Explanation of Responses:

- Immediately prior to completion of the Issuer's initial public offering, the warrants were automatically exercised for shares of Series B Preferred Stock and such shares acquired were automatically converted into shares of the Issuer's Common Stock on a 1 to 1.196 basis, net of shares of Common Stock withheld by the Issuer to cover the exercise price, resulting in the issuance of 185,623 shares of Common Stock.
- The shares are owned by BridgeBio Pharma LLC. The Reporting Person is the chief executive officer and a managing member of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.
- Upon closing of the Issuer's initial public offering, the preferred stock automatically converted into the Issuer's Common Stock on a 1 to 1.196 basis.

Remarks:

/s/ Franco Valle, Attorney-in-Fact 06/22/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.